Location
Areas of Expertise
About Me
Dr. Damien Goldberg is a board-certified ophthalmologist and managing partner at Wolstan and Goldberg Eye Associates in Torrance, California. He is recognized as a leader in laser vision correction (LASIK), refractive cataract surgery, and advanced techniques in corneal and micro-invasive glaucoma surgery. Dr. Goldberg is committed to bringing the latest eye care technologies to his patients, often being among the first to implement new devices and procedures based on his extensive research background.
With over ninety FDA clinical trials as a principal investigator, Dr. Goldberg has a deep involvement in developing new medical devices and medications for eye care. He serves on the FDA committee of the American Society of Cataract and Refractive Surgery (ASCRS) and holds surgical credentials at multiple hospitals and surgery centers in the area, including Torrance Memorial, Little Company of Mary Hospital, and UCLA. This allows him to offer convenient surgical options for his patients.
Dr. Goldberg also holds the position of Chief of the Department of Ophthalmology at Torrance Memorial, an affiliate of Cedar Sinai Medical Center. He is currently welcoming new patients and focuses on providing comprehensive, cutting-edge care for a wide range of eye conditions.
Training

Cornea, External Disease and Refractive Surgery Fellow
2005University of Texas Southwestern
FellowshipDepartment of Ophthalmology
2004Georgetown University / Washington National Eye Center
Residency
Department of Internal Medicine
2001Georgetown University
ResidencyMD and MBA
2000Georgetown University, School of Medicine and The Robert Emmett McDonough School of Business
Medical School
Bachelor of Science with High Honors, Biology, Anthropology and Human Biology
1995Emory University
Undergraduate
Awards & Honors
AAO Achievement Award
2019ASCRS FDA Committee
2018AECOS American Membership Committee
2017Castle Connolly Top Doctors Award
2017OSN Premier Surgeon 300 Innovators in Refractive Cataract Surgery Award
2016Editorial Board of Cataract & Refractive Surgery Today
2015Editorial Board of Ocular Surgery News
2015Co-Editor of Millennial Eye Electronic Periodical
2013
Publications & Press
A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease
Ophthalmology. 2019 Apr 6•2019Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
Clin Ophthalmol. 2019 May 27;13:887-894.•2019
Certifications & Licensure
- Licensed In
- CA
- License Numbers
- A87954


